CD Genomics is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR system, reduce off-target rates, and further explore genetic information related to human health.
New York, United States - December 22, 2022 /MarketersMEDIA/ —
The Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction services, and other related data analysis services. The company is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR system, reduce off-target rates, and further explore genetic information related to human health.
In recent years, CRISPR technology has significantly promoted the innovation of gene therapy for blood diseases, tumors, genetic diseases, and other diseases, which has become a powerful tool in the field of scientific research. However, the CRISPR technology was also demonstrated to consist of shortcomings, in which the 20 bp recognition site has limited specificity, which may cause significant off-target effects and lead to serious consequences eventually.
Although the CRISPR system now has enormous potential in diverse fields, such as animal disease modeling, genetically modified botany, biofuel technology, gene therapy, and drug development, identifying off-target sites in a highly sensitive and thorough manner remains a critical issue.
Commonly used in biological experiments, the CRISPR-Cas system is RNA-directed endonucleases for genome engineering, where off-target effects limit its effectiveness. These off-target sites arise from cleavage of similar genomic regions, including mismatches, insertions, or deletions of one or more base pairs. To get the most out of the CRISPR-Cas9 system and ensure that only the intended sites are split, it is critical to detect every possible off-target site.
Targeted region sequencing is a highly targeted approach that allows researchers to assess genetic variation in specific genomic regions. The ultra-deep sequencing of PCR products (amplicons) facilitates the detection and classification of variants effectively. They enable the true on/off-target mutations of genome editing experimentation to be determined in conjunction with genome-wide off-target detection systems (GUIDE-seq, WGS) at high sensitivity and in a non-biased way.
“To identify CRISPR/Cas-induced on/off-target mutations by deep sequencing of PCR amplicons, we have developed a cost-effective, high-throughput strategy. Based on years of experience in genome editing and assessment of off-target effects, we offer a one-stop alternative to reliably capture mutations induced by sequence-specific nucleases,” commented the senior scientist of CD Genomics.
“We provide a robust method to identify CRISPR/Cas-induced on/off mutations of interest (regions of interest) utilizing deep sequencing of PCR amplicons. At CD Genomics, you will have access to all the specific data regarding on- and off-target mutations, as well as validation of knockout/knock-in alleles, assessment of sgRNA cleavage utilization, detection of homozygosity and heterozygosity, and verification of potential off-target sites,” he added.
About CD Genomics
With a high-performance computing platform and a bioinformatics analysis team dominated by Ph.D. and Master’s degrees, CD Genomics is the second-to-none provider of bioinformatics analysis services. The company takes advantage of cutting-edge bioinformatics analysis technology to conduct research in genomics, transcriptomics, microorganisms, epigenetics, proteomics, metabolomics, single-cell omics, and more.
Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://www.cd-genomics.com/
Release ID: 89086974
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
